Compare NVAX & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | USPH |
|---|---|---|
| Founded | 1987 | 1990 |
| Country | United States | United States |
| Employees | N/A | 5500 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1996 | 1996 |
| Metric | NVAX | USPH |
|---|---|---|
| Price | $10.18 | $60.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $11.33 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 3.6M | 146.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | ★ 309.76 | N/A |
| EPS | N/A | ★ 1.42 |
| Revenue | ★ $1,123,479,000.00 | $780,990,000.00 |
| Revenue This Year | N/A | $10.62 |
| Revenue Next Year | N/A | $6.30 |
| P/E Ratio | ★ N/A | $41.64 |
| Revenue Growth | ★ 64.69 | 16.33 |
| 52 Week Low | $6.20 | $58.55 |
| 52 Week High | $11.85 | $93.50 |
| Indicator | NVAX | USPH |
|---|---|---|
| Relative Strength Index (RSI) | 72.35 | 22.86 |
| Support Level | $7.75 | N/A |
| Resistance Level | $10.42 | $86.52 |
| Average True Range (ATR) | 0.51 | 3.34 |
| MACD | 0.23 | -1.28 |
| Stochastic Oscillator | 81.09 | 8.42 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.